Menopause and Joint Pain: A Physical Therapist's Guide to Programming for Perimenopausal MSK Changes

TL;DR

• Declining estrogen during perimenopause can alter collagen turnover, tendon adaptation, bone remodeling, and muscle protein metabolism. These changes may contribute to joint pain, tendinopathy, reduced muscle mass, and bone loss.
• Physical therapists should screen for symptom onset alongside menstrual changes, assess tendon reactivity and loading history, and identify changes in strength or functional capacity.
• Programming should use progressive resistance and weight-bearing exercise while adjusting tendon loads according to symptom response and recovery.
• This clinician-facing reference applies published musculoskeletal and endocrinology research to assessment, exercise progression, and coordination with physicians or dietitians. It is not a patient handout.

What clinicians mean by menopause-related joint pain

Menopause-related joint pain refers to new or worsening musculoskeletal pain that develops during the menopause transition and may track with hormonal change. Symptoms can begin in perimenopause, when estrogen levels fluctuate and menstrual patterns change, rather than waiting until menopause is confirmed after 12 months without menstruation. The term includes arthralgia and stiffness, but it does not identify a single diagnosis or prove that hormones caused the symptoms.

Physical therapists should look for a temporal pattern. Relevant findings include multi-joint symptoms, reduced recovery after familiar loading, or new tendon complaints that appear alongside cycle changes or vasomotor symptoms. Published prevalence estimates vary because studies use different symptom definitions and cannot always separate hormonal effects from aging, activity changes, or existing pathology.

Menopause-related joint pain and osteoarthritis can coexist, but clinicians should not treat them as interchangeable. Osteoarthritis usually presents through a joint-specific history, examination findings, and a loading pattern consistent with the affected joint. Menopause-related arthralgia may involve several sites and emerge over a shorter period around perimenopause. Assessment should still screen for inflammatory disease, fracture risk, neurologic involvement, and other causes that require medical evaluation.

Why estrogen decline drives joint pain

Declining and fluctuating estrogen exposure can affect joint tissues through receptors present throughout cartilage, synovium, subchondral bone, ligaments, and other connective tissues, a finding that overturned the earlier assumption that joints were unresponsive to estrogen (NIH). Estrogen signaling helps regulate collagen synthesis and extracellular matrix turnover, and in cartilage studies it has been shown to suppress collagen breakdown signals and inflammatory mediators such as COX-2 while supporting glycosaminoglycan synthesis (NIH). Reduced signaling may therefore limit normal tissue maintenance and alter the mechanical behavior of collagen-rich structures.

Estrogen also influences cartilage and synovial activity, and animal models of estrogen deficiency show increased cartilage turnover, surface erosion, and elevated subchondral bone turnover compared to estrogen-intact controls (NIH). Radiographic knee osteoarthritis is roughly three times more common in women aged 45 to 64 than in men of the same age, and in one study 64% of women with knee osteoarthritis reported symptom onset either perimenopausally or within five years of menopause (NIH). Current evidence supports several interacting pathways rather than one established cause of menopausal arthralgia.

Hormonal changes can affect pain perception as well as local tissue biology. A 2025 peer-reviewed review describes perimenopausal estrogen fluctuation as closely linked to knee osteoarthritis pain through three mechanisms: regulation of inflammatory responses, inhibition of cellular senescence and apoptosis, and modulation of neurotransmitters (MDPI). A patient may therefore report diffuse stiffness or new joint pain without a corresponding increase in structural findings on imaging.

Physical therapists should interpret symptom onset within the broader clinical picture. A temporal relationship with menstrual changes or vasomotor symptoms can support a menopause-related contribution, but it does not exclude osteoarthritis, inflammatory arthritis, referred pain, or systemic disease. Assessment should combine hormonal timing with joint examination, load history, symptom behavior, and appropriate referral when the presentation suggests another diagnosis.

Tendinopathy risk during the menopause transition

Tendons may become less tolerant of abrupt loading changes during perimenopause and early postmenopause. Tenocytes carry estrogen receptors, so tendon tissue responds directly to hormonal change, and declining estrogen is associated with decreased collagen synthesis, reduced collagen fibre diameter and density, and increased tissue degradation in preclinical models (NIH). Estrogen-deficient tenocytes also show slower migration and poorer healed-tissue quality in animal models, suggesting estrogen loss impairs repair capacity on its own, separate from chronological aging (NIH). A tendon can therefore remain symptomatic longer when activity volume or intensity rises faster than its capacity to adapt.

Changes in tendon stiffness may also affect load tolerance. Stiffness describes how much a tendon resists deformation, while compliance describes how readily it lengthens under force. Findings on stiffness are inconsistent across animal and human studies, some show increased stiffness with aging and others show decreased or unchanged stiffness, a discrepancy researchers attribute partly to methodology and to collagen cross-linking that can preserve apparent stiffness even as collagen concentration falls (NIH). Menopause does not produce one uniform mechanical change, but altered stiffness can change force transmission and local strain during repeated loading, which may contribute to pain after a sudden increase in running, jumping, lifting, or overhead activity.

Before menopause, women have a lower risk of tendon pathology than men, but after menopause, tendinopathy and tendon rupture incidence becomes similar between women and age-matched men (NIH). A 2026 narrative review identifies the rotator cuff, patellar, gluteal, and Achilles tendons as most commonly affected by overuse-related tendinopathy, and confirms that postmenopausal women show higher susceptibility than men, attributing this to the interplay between estrogen decline, adiposity-related inflammation, and disrupted collagen homeostasis (Journal of Orthopaedic Surgery and Research). Age, metabolic health, training history, and body composition also influence those associations, so hormonal status should inform assessment rather than serve as a stand-alone diagnosis.

Physical therapists should ask whether symptoms began near menstrual cycle changes, menopause symptoms, or a recent increase in load. New tendon pain during this period does not require permanent unloading. It supports a slower progression, closer monitoring of the 24-hour symptom response, and smaller increases in volume or intensity while tendon capacity develops.

Sarcopenia and accelerated muscle mass loss

Perimenopause can accelerate losses in muscle quality, strength, and lean mass before a patient meets formal criteria for sarcopenia. Skeletal muscle fibers carry estrogen receptors directly, and estradiol normally stimulates the muscle satellite cells responsible for repair and regrowth after mechanical stress (Frontiers in Endocrinology). Menopause is also associated with rising pro-inflammatory cytokines, including IL-6 and TNF-alpha, and estradiol normally suppresses inflammation-driven TNF-alpha release that otherwise degrades muscle protein and blunts the muscle's response to training (Frontiers in Endocrinology). Clinicians often describe the resulting pattern as anabolic resistance because muscle requires a stronger training and nutrition stimulus to support adaptation.

Researchers describe sarcopenia onset in women as intimately linked to menopause, a distinct pattern from generic age-related muscle loss, with the menopausal transition associated with declining estradiol alongside falling bone density, muscle mass, and muscle strength together (Frontiers in Endocrinology). Pain, sleep disruption, and reduced activity can further reduce loading exposure during the same period.

Reported rates of lean mass loss vary with age, activity, diet, and measurement method, so a universal annual percentage does not fit every patient. The clinically relevant feature is timing. A patient may enter the menopause transition while muscle loss is becoming easier to initiate and harder to reverse through low-intensity activity alone.

Resistance training should therefore begin or progress during perimenopause rather than waiting for an older-age sarcopenia diagnosis. Programming can start at a tolerable baseline, then increase external load, volume, or exercise complexity according to symptoms and performance. Clinicians should track strength and functional capacity alongside body composition because those measures often reveal meaningful change sooner.

Bone density loss and fracture risk timing

Estrogen decline accelerates bone remodeling because osteoclast-mediated resorption increases faster than osteoblast-mediated formation. Trabecular bone, including the lumbar spine, can lose density quickly during this period. Cortical sites such as the femoral neck also lose density, although their remodeling pattern differs.

Bone loss accelerates around the final menstrual period rather than beginning only after menopause. The Study of Women's Health Across the Nation tracks bone mineral density annually at the lumbar spine, hip, and whole body using DXA imaging, and its published analyses of this cohort identify a "transmenopausal interval," one year before through two years after the final menstrual period, in which bone loss accelerates sharply compared to the years before or after it. Rates slow once this window closes, making late perimenopause and early postmenopause a clinically important period for assessment and intervention.

Fracture risk depends on more than bone mineral density. Muscle strength, balance, fall exposure, prior fractures, medication use, and nutrition also affect risk. Physical therapists should screen for these factors and refer for medical evaluation when history suggests osteoporosis or elevated fracture risk.

Load-bearing exercise provides the mechanical strain that bone requires to maintain or increase strength. Programming during this transition should therefore include progressive resistance and weight-bearing impact where appropriate, rather than relying mainly on low-load mobility work. Exercise selection and intensity should reflect baseline strength, skeletal risk, symptoms, and previous training exposure.

What to change in programming

• Add menopause timing to the assessment. Ask whether new joint pain, morning stiffness, or tendon symptoms began alongside menstrual changes, vasomotor symptoms, or sleep disruption. Record hormone therapy use, recent training changes, prior fractures, dietary restriction, and changes in recovery. Continue to assess local pathology and screen for inflammatory disease, neurologic involvement, unexplained weight change, night pain, and other findings that warrant medical review.

• Establish capacity before prescribing progression. Measure strength in the affected region and use repeatable functional tests that reflect the patient’s goals. For tendon presentations, document a load-tolerance task such as heel raises, step-downs, or resisted shoulder work. Baseline measures help you distinguish ordinary post-exercise symptoms from a sustained loss of capacity.

• Prioritize progressive resistance training for muscle and bone. A practical starting structure uses two or three sessions each week with major movement patterns selected for the patient’s function and fracture risk. Deconditioned patients may begin with one or two sets at a manageable effort, then progress toward two or three sets of roughly 6 to 12 repetitions. Increase resistance when the patient completes the target volume with stable technique and expected recovery. Higher-load resistance and weight-bearing impact provide a stronger skeletal stimulus, but osteoporosis, pelvic floor symptoms, joint irritability, and fall risk may require modified exercise selection.

• Progress one loading variable at a time. Increase resistance, repetitions, sets, movement range, or impact exposure rather than changing several variables during the same week. Track symptoms during exercise and over the following 24 hours. Persistent next-day aggravation suggests that the current dose exceeds recoverable capacity and needs adjustment.

• Keep reactive tendons active within a tolerable range. Complete rest can reduce capacity further, so replace provocative loading with a dose the tendon can currently tolerate. Isometric exercise may provide a useful entry point when dynamic loading remains irritable, although analgesic response varies. Progress toward slow isotonic work and then heavier, faster, or energy-storage tasks when symptoms and next-day function remain stable. Sport-specific loading should follow restored strength and repeated tolerance to simpler tasks.

• Build planned review points into home programming. Physitrack’s home exercise program builder lets clinicians deliver phased resistance and tendon-loading programs, then adjust them as capacity changes. PhysiApp records completed exercises, sets, repetitions, pain, and difficulty at the session level. You can use those patterns to identify missed doses, stalled progression, or repeated symptom flares between visits.

• Coordinate when medical or nutritional factors affect loading. Refer to a physician when symptoms suggest inflammatory disease, fragility fracture, significant bone loss, or another nonmechanical cause. A physician should lead decisions about hormone therapy and assess relevant risks. Consider dietitian input when low energy intake or inadequate protein, calcium, or vitamin D may limit adaptation, especially when restrictive eating, gastrointestinal disease, or low body weight complicates the picture.

Coordinating care beyond the clinic

Physical therapists should refer patients for medical evaluation when joint symptoms cannot be reasonably explained by mechanical loading or the menopause transition. Referral triggers include persistent joint swelling, marked morning stiffness, unexplained night pain, systemic symptoms, suspected stress fracture, or rapid functional decline. A physician can evaluate inflammatory disease, metabolic contributors, medication effects, and the need for bone density testing.

Communication should connect symptom onset with the patient’s hormonal timeline and document the clinical response to loading. Share relevant menstrual changes, pain distribution, tendon irritability, fracture history, strength changes, and any loss of load tolerance. Physical therapists may discuss how hormone therapy could affect rehabilitation planning, but prescribing decisions belong to a qualified medical clinician.

Dietitian referral may help when dietary history suggests inadequate protein or low calcium and vitamin D intake. The physical therapist can provide training demands and functional goals so the dietitian can assess whether nutrition supports the prescribed workload.

Adherence records give other clinicians a clearer view of what the patient completed between visits. Physitrack can capture exercise completion, sets and repetitions, and session-level pain and difficulty ratings. Exported reports can support multidisciplinary review without positioning exercise data as a substitute for medical or nutritional assessment.

Key takeaway for clinical practice

Perimenopause creates an identifiable MSK risk window in which hormonal changes may coincide with new joint pain, tendon reactivity, and loss of muscle and bone. Physical therapists should ask about symptom timing and menstrual changes when clinically appropriate, then account for those findings alongside the standard differential diagnosis.

Clinic directors should formalize a menopause-informed protocol that supports consistent screening and early loading intervention. Clinicians can begin progressive resistance and weight-bearing exercise before major losses accumulate, while adjusting tendon load to current tolerance rather than avoiding load. The protocol should also define referral pathways when symptoms suggest systemic disease, fracture risk, or a need for medical or nutritional review.

Perguntas mais frequentes 

Does hormone therapy change exercise prescription?

Hormone therapy may affect symptoms and tissue health, but it does not create a separate exercise protocol. Clinicians should base Physitrack programs on current capacity, symptom response, bone health, and established precautions rather than hormone therapy status alone. Medical coordination can clarify whether symptom changes require reassessment or a temporary load adjustment.

How can physical therapists differentiate menopausal arthralgia from osteoarthritis?

Menopausal arthralgia often involves new or fluctuating pain across several joints near the menopause transition, while osteoarthritis more often produces persistent, localized symptoms with corresponding clinical or imaging findings. Physical therapists should document symptom timing, morning stiffness, joint distribution, swelling, mechanical findings, and response to loading before assigning a Physitrack program. Persistent swelling, systemic symptoms, rapid deterioration, or diagnostic uncertainty warrants medical evaluation.

How quickly can tendon load tolerance improve with treatment?

Tendon load tolerance can improve over several weeks, but the rate depends on symptom duration, baseline capacity, tendon site, recovery, and loading consistency. Physitrack adherence records and symptom feedback can help clinicians judge whether prescribed isometrics or progressive resistance remain tolerable between visits. Clinicians should progress against repeated functional measures rather than a fixed menopause-specific timeline.